The FDA held its first public hearing May 31 to evaluate the safety and efficacy of CBD products, which have exploded onto the market claiming everything from pain relief to depression support. The FDA planned to delve into manufacturing, product quality and concentration, marketing and effects of long-term use to
This content is restricted to site members. If you are an existing user, please log in. New users may register below.